Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don L Gibbons

Showing results (11-20 of 198) with videos related to

Pageof 20
Sort By:
Cold Spring Harbor Perspectives in Medicine|September 28, 2021
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerTina Cascone, Jared Fradette, Monika Pradhan, et al.
Molecular Cancer Research : MCR|January 21, 2014
Smoking, p53 mutation, and lung cancerDon L Gibbons, Lauren A Byers, Jonathan M Kurie
Translational Lung Cancer Research|February 11, 2021
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancerMonika Pradhan, Mathieu Chocry, Don L Gibbons, et al.
Cells|May 14, 2022
Dance of The Golgi: Understanding Golgi Dynamics in Cancer MetastasisRakhee Bajaj, Amanda N Warner, Jared F Fradette, et al.
The Journal of Clinical Investigation|January 3, 2018
The fibrotic tumor stromaMitsuo Yamauchi, Thomas H Barker, Don L Gibbons, et al.
The New England Journal of Medicine|March 11, 2011
Treatment of non-small-cell lung cancer with erlotinib or gefitinibVince D Cataldo, Don L Gibbons, Román Pérez-Soler, et al.
Clinical Lung Cancer|April 18, 2020
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial ReportPierre-Olivier Gaudreau, J Jack Lee, John V Heymach, et al.
Oncoimmunology|July 9, 2015
The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progressionLimo Chen, John V Heymach, F Xiao-Feng Qin, et al.
Cancer|July 7, 2011
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigmDon L Gibbons, Sabrina Pricl, Hagop Kantarjian, et al.
Molecular Oncology|July 3, 2013
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experimentsErik Laurini, Paola Posocco, Maurizio Fermeglia, et al.
Pageof 20

Showing results (11-20 of 198) with videos related to

Sort By:
Pageof 20
Cold Spring Harbor Perspectives in Medicine|September 28, 2021
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerTina Cascone, Jared Fradette, Monika Pradhan, et al.
Molecular Cancer Research : MCR|January 21, 2014
Smoking, p53 mutation, and lung cancerDon L Gibbons, Lauren A Byers, Jonathan M Kurie
Translational Lung Cancer Research|February 11, 2021
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancerMonika Pradhan, Mathieu Chocry, Don L Gibbons, et al.
Cells|May 14, 2022
Dance of The Golgi: Understanding Golgi Dynamics in Cancer MetastasisRakhee Bajaj, Amanda N Warner, Jared F Fradette, et al.
The Journal of Clinical Investigation|January 3, 2018
The fibrotic tumor stromaMitsuo Yamauchi, Thomas H Barker, Don L Gibbons, et al.
The New England Journal of Medicine|March 11, 2011
Treatment of non-small-cell lung cancer with erlotinib or gefitinibVince D Cataldo, Don L Gibbons, Román Pérez-Soler, et al.
Clinical Lung Cancer|April 18, 2020
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial ReportPierre-Olivier Gaudreau, J Jack Lee, John V Heymach, et al.
Oncoimmunology|July 9, 2015
The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progressionLimo Chen, John V Heymach, F Xiao-Feng Qin, et al.
Cancer|July 7, 2011
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigmDon L Gibbons, Sabrina Pricl, Hagop Kantarjian, et al.
Molecular Oncology|July 3, 2013
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experimentsErik Laurini, Paola Posocco, Maurizio Fermeglia, et al.
Pageof 20